Compare LEXX & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEXX | XCUR |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.7M | 26.6M |
| IPO Year | N/A | N/A |
| Metric | LEXX | XCUR |
|---|---|---|
| Price | $0.91 | $5.96 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | 167.8K | ★ 1.8M |
| Earning Date | 01-09-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $705,923.00 | N/A |
| Revenue This Year | $13.35 | N/A |
| Revenue Next Year | $78.83 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 52.05 | N/A |
| 52 Week Low | $0.77 | $3.10 |
| 52 Week High | $2.43 | $22.99 |
| Indicator | LEXX | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 39.27 | 55.65 |
| Support Level | $1.05 | $5.15 |
| Resistance Level | $1.44 | $6.89 |
| Average True Range (ATR) | 0.10 | 1.04 |
| MACD | -0.00 | 0.13 |
| Stochastic Oscillator | 11.10 | 39.72 |
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.